Previous 10 | Next 10 |
Deals and Financings Ally Bridge Group, a Hong Kong-New York life science investment firm, announced it has led $140 million of investments in three new medical device companies, bringing its 18-month total to more than $500 million in private life science companies. ABG's latest investments...
TRACON Pharmaceuticals (NASDAQ: TCON ) +25% on envafolimab deal . More news on: TRACON Pharmaceuticals, Inc., Care.com, Inc., Marinus Pharmaceuticals, Inc., Stocks on the move, Read more ...
TRACON Pharmaceuticals (NASDAQ: TCON ) is up 39% premarket on signing a collaborative partnership agreement with 3D Medicines (Beijing) Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd., for the development of envafolimab, also known as KN035, a PD-L1 single...
Company to Host Investor Conference Call Today at 8:30 a.m. ET / 5:30 a.m. PT Envafolimab represents a potential best-in-class PD-L1 inhibitor that is injectable subcutaneously without the need for an adjuvant Envafolimab has been dosed in more than 650 patients in the U.S., China...
SAN DIEGO, Nov. 08, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer as well as wet age-related macular degeneration through a license to Sante...
TRACON Pharmaceuticals, Inc. (TCON) Q3 2019 Earnings Conference Call November 05, 2019 4:30 PM ET Company Participants Charles Theuer – President and Chief Executive Officer Scott Brown – Chief Accounting Officer Conference Call Participants Bert Hazlett –...
Tracon (NASDAQ: TCON ): Q1 GAAP EPS of -$0.17 beats by $0.03 . More news on: TRACON Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SAN DIEGO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer as well as wet age-related macular degeneration through a license to...
SAN DIEGO, Oct. 29, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration through our license to Santen Pha...
TRACON Pharmaceuticals ( TCON -8.6% ) has entered into a Common Stock Purchase Agreement of up to $15M with Aspire Capital Fund. More news on: TRACON Pharmaceuticals, Inc., Read more ...
News, Short Squeeze, Breakout and More Instantly...
TRACON Pharmaceuticals Inc. Company Name:
TCON Stock Symbol:
OTCMKTS Market:
TRACON Pharmaceuticals Inc. Website:
SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (OTCQB: TCON) today announced that the Company has terminated its employees and will wind down its operations. This decision was made at a special meeting of the board of directors. The board of directors appointed Craig R....
A look at the top 10 most actives in the United States Yoshitsu Co. Ltd (TKLF) rose 103.4% to $0.623 on volume of 309,019,720 shares Maxeon Solar Technologies Ltd. (MAXN) rose 11.2% to $0.2524 on volume of 226,231,487 shares NVIDIA Corporation (NVDA) fell 1.6% to $126.36 on volume of 208,...
A look at the top 10 most actives in the United States American Rebel Holdings Inc. (AREB) rose 60.3% to $0.83355 on volume of 56,112,820 shares DatChat Inc. (DATS) rose 71.2% to $1.78 on volume of 33,845,116 shares Autonomix Medical Inc. (AMIX) rose 97.4% to $1.22 on volume of 33,054,234...